Pluri secures US$3.5M in private placement to expand cell-based technology
ISRAEL – Israeli biotechnology company Pluri is raising US$3.5 million through a private placement as it continues to strengthen its position in the cell-based technology sector.
The investment comes from Merchant Adventure Fund, a long-term shareholder, and follows a previous US$6.5 million placement led by global investor Alejandro Weinstein.
With these two transactions, the company has secured US$10 million in recent funding.
The latest private placement is expected to close on or around February 20, 2025, pending regulatory approvals and other closing conditions.
As part of the agreement, Pluri will issue 759,219 shares at US$4.61 per share and grant warrants for an additional 45,553 shares at an exercise price of US$5.568.
Pluri plans to use the capital to advance its work in pharmaceuticals, food technology, and agriculture, areas where cell-based solutions are gaining traction.
CEO Yaky Yanay said the investment reflects continued confidence from shareholders in the company’s direction and execution capabilities.
Pluri is focusing on its proprietary 3D cell expansion technology, which allows for scalable and cost-effective production of cell-based products.
The company aims to use this platform to address food security, sustainability concerns, and advancements in regenerative medicine.
As consumer demand for ethical and sustainable alternatives increases, the cell-based industry is attracting significant interest from investors.
Traditional livestock farming is under scrutiny for its environmental footprint, leading companies like Pluri to explore alternatives with lower ecological impact.
Pluri has recently entered discussions to acquire Kokomodo, a move that could allow it to expand into the cacao sector.
The company’s recent funding aligns with a broader trend of investment in biotechnology, particularly in sustainable food production.
By scaling its operations, Pluri aims to provide viable alternatives to conventional food manufacturing while addressing global resource challenges.
Investors are increasingly viewing cell-based technologies as a way to develop solutions that balance economic viability with environmental sustainability.
Pluri specializes in cell-based innovations designed to tackle challenges in food security, healthcare, and sustainability.
Its patented 3D cell expansion system supports mass production of cells, positioning the company as a key player in regenerative medicine, food technology, and agriculture.
Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.
